OQS
MLYS icon

Occudo Quantitative Strategies’s Mineralys Therapeutics MLYS Stock Holding History

Occudo Quantitative Strategies’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,489
Closed -$214K – 1046
2023
Q3 		$214K Buy
+22,489
New +$293K 0.03% 781

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Occudo Quantitative Strategies's MLYS Position: Q4 2023 in Review

Occudo Quantitative Strategies sold out of Mineralys Therapeutics (MLYS) in Q4 2023, closing a stake of 22,489 shares — an estimated $214K sold.

Occudo Quantitative Strategies first reported a position in MLYS in Q3 2023 and held it in 1 quarter. The position peaked at $214K in Q3 2023. 87 funds tracked by Wall St. Rank hold MLYS as of Q4 2023.

  • Occudo Quantitative Strategies reported no remaining Mineralys Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 22,489 Mineralys Therapeutics shares in Q4 2023, an estimated $214K.
  • Occudo Quantitative Strategies first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Mineralys Therapeutics position peaked at $214K in Q3 2023.
  • 87 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.